Plain-English translation of NCT06567704 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a research study designed to understand cancer-related fatigue—extreme tiredness that many patients experience while taking immune checkpoint inhibitors for advanced lung cancer. The study involves talking with researchers about your fatigue experience at two different time points. By learning more about how fatigue affects your daily life, the research team hopes to eventually develop better ways to help patients manage this common side effect.
Many lung cancer patients taking immunotherapy report significant fatigue that interferes with their daily activities, but doctors don't yet fully understand why this happens or the best ways to help. This study aims to gather patient experiences so that healthcare providers can better support people going through this treatment.
You likely qualify if…
You likely don't qualify if…
You would participate in two interviews—one initial meeting and one follow-up conversation. During the first interview, you'll complete a brief seven-question survey about your fatigue, and then discuss your experience with a researcher. In the follow-up interview, you'll talk about whether your fatigue has changed and share your thoughts about physical activity. The interviews take place at either Levine Cancer Institute or Atrium Health Wake Forest Baptist Comprehensive Cancer Center, and the study is designed to fit around your ongoing treatment schedule.
AI-generated summary from trial data · Aug 17, 2026 · Not medical advice
United States
Sponsor
Wake Forest University Health Sciences
Collaborators
Atrium Health Levine Cancer Institute
Enrollment target
~20 participants
Started
March 2025
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Megan Lattanze
Atrium Health Levine Cancer
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.